To estimate the fracture risk among postmenopausal females with osteoporosis following discontinuing BP treatment.
Biophosphates (BP) are the first line drug used
to reduce the risk of vertebral, hip, and non-vertebral fractures in
postmenopausal women with osteoporosis. For most postmenopausal womens with
osteoporosis the benifit of BP outweight the risks. Therefore this study
reported the 40% incresed of clinical fractures in womens who took a BP drug
holiday.
To estimate the fracture risk among postmenopausal
females with osteoporosis following discontinuing BP treatment.
A total of 108 postmenopausal females with
osteoporosis who had undergone a “drug holiday” or continued therapy following
first-line BP therapy were selected for analysis. The appearance of new
clinical fractures at the time of follow-up was also investigated. The
associations between BP “drug holiday” and the appearance of clinical fractures
while checking for confounding factors were identified applying the Cox proportional
hazards models. Log-rank tests and Kaplan-Meier curves were used to analyse the
survival without new clinical fractures.
The patients obtained
Risedronate, Ibandronate, Alendronate, and Zoledronic acid. One hundred
sixty-six patients showed 6 to 36 months of follow-up. The rates of new
clinical fractures at follow-up were 16.1% for “drug holiday” group and
11.9%for another group. After full adjustment, the “drug holiday” patients
showed 1.40 hazard ratio of new clinical fractures.
The risk of recently found clinical fractures was 40%
greater among patients who received a Bisphosphonate drug holiday after the
first-line BP therapy.
Osteoporosis International
Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk
M. A. Mignot et al.
Comments (0)